TY - JOUR
T1 - Cognitive response to pharmacological treatment for depression in Alzheimer disease
T2 - Secondary outcomes from the depression in Alzheimer's disease study (DIADS)
AU - Munro, Cynthia A.
AU - Brandt, Jason
AU - Sheppard, Jeannie Marie E.
AU - Steele, Cynthia D.
AU - Samus, Quincy M.
AU - Steinberg, Martin
AU - Rabins, Peter V.
AU - Lyketsos, Constantine G.
N1 - Funding Information:
This work was supported by Grant 1 R01MH56511 from DIADS. Drs. Rabins and Lyketsos have received honoraria from Pfizer, Inc. for presentations over the past year.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004
Y1 - 2004
N2 - Objective: The authors assessed the cognitive effects of depression treatment with sertraline in patients with Alzheimer disease (AD) and major depression. Methods: Forty-four patients with probable AD and major depression were enrolled in a double-blind, placebo-controlled clinical trial of sertraline. Cognitive testing was done at baseline and at 3-week intervals throughout the 12-week study. At the 12th week, subjects were categorized by treatment response (full, partial, or no response). Cognitive data from 41 participants who completed three or more testing sessions and 36 who completed all five study visits were included in the analyses. Results: Neither improved mood nor use of sertraline was associated with cognitive change over time in AD patients. Post-hoc exploration of the data, however, suggested a sex difference in cognitive response to sertraline such that women treated with sertraline demonstrated improved cognition compared with women on placebo, whereas men treated with sertraline worsened significantly in cognition compared with men on placebo. Conclusions: In this study, among depressed AD patients after treatment with sertraline or placebo, there was no evidence that improved mood was associated with cognitive improvement. Future studies aimed at increasing power to detect mood as well as medication effects will be valuable in determining the relationship between cognition and treatment of depression in AD patients.
AB - Objective: The authors assessed the cognitive effects of depression treatment with sertraline in patients with Alzheimer disease (AD) and major depression. Methods: Forty-four patients with probable AD and major depression were enrolled in a double-blind, placebo-controlled clinical trial of sertraline. Cognitive testing was done at baseline and at 3-week intervals throughout the 12-week study. At the 12th week, subjects were categorized by treatment response (full, partial, or no response). Cognitive data from 41 participants who completed three or more testing sessions and 36 who completed all five study visits were included in the analyses. Results: Neither improved mood nor use of sertraline was associated with cognitive change over time in AD patients. Post-hoc exploration of the data, however, suggested a sex difference in cognitive response to sertraline such that women treated with sertraline demonstrated improved cognition compared with women on placebo, whereas men treated with sertraline worsened significantly in cognition compared with men on placebo. Conclusions: In this study, among depressed AD patients after treatment with sertraline or placebo, there was no evidence that improved mood was associated with cognitive improvement. Future studies aimed at increasing power to detect mood as well as medication effects will be valuable in determining the relationship between cognition and treatment of depression in AD patients.
UR - http://www.scopus.com/inward/record.url?scp=84903195940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903195940&partnerID=8YFLogxK
U2 - 10.1097/00019442-200409000-00007
DO - 10.1097/00019442-200409000-00007
M3 - Article
AN - SCOPUS:84903195940
SN - 1064-7481
VL - 12
SP - 491
EP - 498
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 5
ER -